G. Whiteside

发表

CNS penetration of small molecules following local inflammation, widespread systemic inflammation or direct injury to the nervous system.

J. Kennedy, P. Lu, C. Gonzales, 2009, Life sciences.

A Review of the NOP (ORL-1)-Nociceptin/Orphanin FQ System Covering Receptor Structure, Distribution, Role in Analgesia and Reward and Interactions with Other Receptors

D. Kyle, G. Whiteside, 2013 .

Pharmacological evaluation of NSAID-induced gastropathy as a "Translatable" model of referred visceral hypersensitivity

M. Hummel, G. Whiteside, T. Knappenberger, 2017, World journal of gastroenterology.

Depression-like phenotype following chronic CB1 receptor antagonism

C. Beyer, J. Dwyer, B. Platt, 2010, Neurobiology of Disease.

Pharmacological Characterization of the Muscarinic Agonist (3R,4R)-3-(3-Hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983) in in Vitro and in Vivo Models of Chronic Pain

L. Leventhal, N. R. Sullivan, Philip G. Jones, 2007, Journal of Pharmacology and Experimental Therapeutics.

Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease.

L. Leventhal, S. Glasson, J. Kennedy, 2010, Osteoarthritis and cartilage.

1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.

L. Leventhal, E. Koury, D. Deecher, 2010, Journal of medicinal chemistry.

Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats

S. Rawls, E. Walker, G. Whiteside, 2009, Psychopharmacology.

Purinergic receptor-mediated morphological changes in microglia are transient and independent from inflammatory cytokine release.

E. Kaftan, J. Dunlop, R. Martone, 2010, European journal of pharmacology.

Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy

L. Koetzner, Gary Lee, Y. Rotshteyn, 2005, Neuropharmacology.

Measuring and realizing the translational significance of preclinical in vivo studies of painful osteoarthritis.

M. Hummel, G. Whiteside, Garth T. Whiteside, 2017, Osteoarthritis and cartilage.

Pharmacological characterisation of a rat model of incisional pain

K. Walker, G. Whiteside, L. Mark, 2004, British journal of pharmacology.

Species‐specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers

B. Bingham, L. Resnick, J. Kennedy, 2007, British journal of pharmacology.

A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.

K. Valenzano, G. Whiteside, L. Mark, 2005, European journal of pharmacology.

The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists.

K. Valenzano, G. Whiteside, G. P. Lee, 2007, Current medicinal chemistry.

Advances in the development of novel analgesics

W. Childers, A. Gilbert, J. Kennedy, 2008 .

Pain is a salient “stressor” that is mediated by corticotropin-releasing factor-1 receptors

J. Kennedy, P. Lu, M. Hummel, 2010, Neuropharmacology.

Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.

D. Deecher, E. Trybulski, G. Whiteside, 2010, Bioorganic & medicinal chemistry letters.

Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).

L. Leventhal, D. Deecher, E. Trybulski, 2010, Journal of medicinal chemistry.

Particulate levodopa nose-to-brain delivery targets dopamine to the brain with no plasma exposure.

A. Schätzlein, I. Uchegbu, I. Kubajewska, 2022, International journal of pharmaceutics.

DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: II. In Vivo Pharmacological Characterization in the Rat

J. Pomonis, Y. Rotshteyn, K. Walker, 2004, Journal of Pharmacology and Experimental Therapeutics.

DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.

M. Fundytus, J. Pomonis, Y. Rotshteyn, 2004, The Journal of pharmacology and experimental therapeutics.

Predictive validity of animal pain models? A comparison of the pharmacokinetic–pharmacodynamic relationship for pain drugs in rats and humans

L. Leventhal, G. Whiteside, A. Adedoyin, 2008, Neuropharmacology.

Dynamic Changes in the MicroRNA Expression Profile Reveal Multiple Regulatory Mechanisms in the Spinal Nerve Ligation Model of Neuropathic Pain

Wei Liu, Yizheng Li, Seena K. Ajit, 2011, PloS one.

Preclinical Pharmacological Approaches in Drug Discovery for Chronic Pain.

J. Pomonis, J. Kennedy, G. Whiteside, 2016, Advances in pharmacology.

Loss of Retrograde Endocannabinoid Signaling and Reduced Adult Neurogenesis in Diacylglycerol Lipase Knock-out Mice

M. Pangalos, Gareth Williams, F. Walsh, 2010, The Journal of Neuroscience.

An industry perspective on the role and utility of animal models of pain in drug discovery

J. Pomonis, Garth T. Whiteside, James D. Pomonis, 2013, Neuroscience Letters.

Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders.

F. Liu, K. Marquis, M. Pangalos, 2009, Current molecular pharmacology.

Genetic and Functional Analysis of Human P2X5 Reveals a Distinct Pattern of Exon 10 Polymorphism with Predominant Expression of the Nonfunctional Receptor Isoform

P. Chanda, Yuchen Bai, D. Vasilyev, 2010, Molecular Pharmacology.

Neuropathy-induced osteopenia in rats is not due to a reduction in weight born on the affected limb.

K. Walker, G. Whiteside, T. Bunton, 2006, Bone.

Consideration of Pharmacokinetic Pharmacodynamic Relationships in the Discovery of New Pain Drugs

J. Kennedy, G. Whiteside, 2010 .

Monoacylglycerol Lipase Activity Is a Critical Modulator of the Tone and Integrity of the Endocannabinoid System

M. Pangalos, P. Chanda, David S. Garbe, 2010, Molecular Pharmacology.

Targeting CB2 receptors and the endocannabinoid system for the treatment of pain

P. Anand, A. Hohmann, C. Fowler, 2009, Brain Research Reviews.

A-317491, a selective P2X3/P2X2/3 receptor antagonist, reverses inflammatory mechanical hyperalgesia through action at peripheral receptors in rats.

Gary Lee, M. Niosi, Gang Wu, 2004, European journal of pharmacology.

Ensuring transparency and minimization of methodologic bias in preclinical pain research: PPRECISE considerations

Gillian L. Currie, S. McMahon, A. Basbaum, 2015, Pain.

Robustness of arterial blood gas analysis for assessment of respiratory safety pharmacology in rats.

L. Koetzner, M. Hummel, G. Whiteside, 2016, Journal of pharmacological and toxicological methods.

Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models

L. Leventhal, B. Strassle, P. Lu, 2009, Brain Research.

WAY‐318068: a novel, potent and selective noradrenaline re‐uptake inhibitor with activity in rodent models of pain and depression

P. Zhang, L. Leventhal, C. Beyer, 2010, British journal of pharmacology.

Anatomical localization and expression pattern for the NMDA-2D receptor subunit in a rat model of neuropathic pain

E. Kaftan, B. Strassle, M. Hummel, 2008, Neuroscience.

The Role of Central and Peripheral μ Opioid Receptors in Inflammatory Pain and Edema: A Study Using Morphine and DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-acetic Acid)

K. Walker, G. Whiteside, Jamie M. Boulet, 2005, Journal of Pharmacology and Experimental Therapeutics.

Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression

J. Brennan, J. Dwyer, R. Ring, 2013, Neuropharmacology.

The persistence of a long-term negative affective state following the induction of either acute or chronic pain

P. Lu, M. Hummel, G. Whiteside, 2008, PAIN.

1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.

D. Deecher, P. Mahaney, E. Trybulski, 2009, Journal of medicinal chemistry.

Pharmacology of 2-[4-(4-Chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: A Potent, Broad-Spectrum State-Dependent Sodium Channel Blocker for Treating Pain States

R. B. Carter, J. Pomonis, D. Hogenkamp, 2006, Journal of Pharmacology and Experimental Therapeutics.

Unrestricted Weight Bearing as a Method for Assessment of Nociceptive Behavior in a Model of Tibiofemoral Osteoarthritis in Rats

L. Arendt-Nielsen, M. Hummel, G. Whiteside, 2013 .

A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile

L. Arendt-Nielsen, R. Kapil, D. Kyle, 2016, Pain.

Genetic and Functional Analysis of Human P2X5 Reveals a Distinct Pattern of Exon 10 Polymorphism with Predominant Expression of the Nonfunctional Receptor Isoform

P. Chanda, Yuchen Bai, D. Vasilyev, 2010, Molecular Pharmacology.

Predictive validity of animal pain models? A comparison of the pharmacokinetic–pharmacodynamic relationship for pain drugs in rats and humans

G. Whiteside, A. Adedoyin, Liza Leventhal, 2008, Neuropharmacology.

CNS penetration of small molecules following local inflammation, widespread systemic inflammation or direct injury to the nervous system.

J. Kennedy, P. Lu, C. Gonzales, 2009, Life sciences.